Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNAX103
- Development stage
- Preclinical
- Lead developer
- TNAX Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TNAX103 is a humanized monoclonal antibody targeting CD300A, developed as an efferocytosis promoter and neuroprotectant. It fundamentally inhibits ischemia-reperfusion injury by blocking the release of damage-associated molecular patterns (DAMPs) upstream in the inflammatory cascade. The drug is being investigated primarily for acute ischemic stroke, where it has demonstrated efficacy in preclinical models by reducing infarct volume and improving neurological outcomes. Additional potential indications include acute kidney injury (AKI), spinal cord injury (SCI), and acute myocardial infarction (AMI). TNAX103 works by interfering with the binding of CD300A to dead cells, thereby enhancing efferocytosis and reducing inflammation[1][2][5][7].
- Other names
- anti-CD300A monoclonal antibodyanti-CD-300A monoclonal antibodyanti-CD 300A monoclonal antibodyhumanized anti-CD300A mAb
02
Targets
CD300A (CD300A molecule)
Beyond the preview
Go deeper on TNAX103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNAX103.